Cure My Disease

Don't miss your cure!

 Log in / Sign up

MS fatigue study tests l-carnitine supplement

NCT ID NCT01149525

Symptom relief Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether L-carnitine, a natural supplement, can reduce fatigue in people with multiple sclerosis (MS). About 60 adults with MS who had significant fatigue took either L-carnitine or a placebo, then switched. The goal was to see if L-carnitine improved fatigue scores and quality of life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

59 people

The number who actually took part.

Start date

Jun 2010

Finished

Jul 2013

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18 years old and older * Relapsing remitting (RR) secondary progressive (SP) or primary progressive multiple sclerosis according to McDonald 2005 (Polman) MS diagnostic criteria. * Affected of fatigue for more than 3 months with global score on Modified Fatigue Impact Scale (MFIS)\>45. * Indication of treatment of fatigue to the appreciation of the neurologist. * Expanded Disability Status Scale (EDSS) not exceeding 6.0. * Information and comprehensive agreement signed by patient and the investigator. * Subject affiliated to health insurance coverage. Exclusion Criteria: * Patients with serious unstable disease : * recurrent or serious relapses * rapidly ongoing disability impairment in the preceding 6 months * serious or non stabilized depression * Patients starting a new disease modifying therapy, immunosuppression or antidepressant therapy less than 3 months ago or not stabilized. * Patients with a treatment of fatigue or of other condition that may interfere with fatigue evaluation to the appreciation of the neurologist. * Energy drinks consumption or toxicomania. * All other reasons to the opinion of the neurologist that may impair study management, especially patient compliance, neuro-psychological disorders that may input questionnaires filling. * Person under protection of the law. * Participation in other clinical trials (allowing for exceptions, after recommendation from the scientific council).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple sclerosis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple sclerosis

Contacts and locations

Locations

  • University Hospital

    Fort de France, 97261, France

  • University Hospital, Hospital Central

    Nancy, 54034, France

  • University Hospital, Hospital Dupuytren

    Limoges, 87042, France

  • University Hospital, Hospital Laënnec

    Nantes, 44093, France

  • University Hospital, Hospital Pasteur

    Nice, 06000, France

  • University Hospital, Hospital Pellegrin

    Bordeaux, 33076, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.